| “Treat to target” et polyarthrite rhumatoïde B Combe | | |
| 078 Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24 … O Zamani, B Combe, HP Tony, J Sanchez Burson, H Tahir, M Østergaard, ... Rheumatology 55 (suppl_1), i93-i93, 2016 | 1 | 2016 |
| 079 Abatacept Plus Methotrexate can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early … P Emery, G Burmester, V Bykerk, B Combe, DE Furst, M Maldonado, ... RHEUMATOLOGY-LONDON THEN OXFORD-BRITISH SOCIETY FOR RHEUMATOLOGY- 55 (1 …, 2016 | | 2016 |
| 087 On Drug and Drug-Free Remission by Baseline Disease Duration in the Avert Trial: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis V Bykerk, G Burmester, B Combe, DE Furst, T Huizinga, D Wong, P Emery Rheumatology 55 (suppl_1), i97-i98, 2016 | | 2016 |
| 1: CAS: 528: DC% 2BC2sXosVWgsr4% 3D: Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors … P Nash, B Kirkham, M Okada, P Rahman, B Combe, GR Burmester Lancet, 2317-2327, 2017 | 7 | 2017 |
| 103. Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized … E Keystone, R Landewé, R van Vollenhoven, B Combe, V Strand, ... Rheumatology 53 (suppl_1), i96-i96, 2014 | | 2014 |
| 10th World Congress on Osteoarthritis F Berenbaum, L Sandell, VB Kraus, B Combe, LJ Crofford, PD Delmas, ... | | |
| 13th Mediterranean Congress of Rheumatology 18-21 November 2009, Cavtat, Crotia Abstracts B Combe CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 27 (5), 705-705, 2009 | | 2009 |
| 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative D Aletaha, T Neogi, AJ Silman, J Funovits, DT Felson, CO Bingham III, ... Arthritis & rheumatism 62 (9), 2569-2581, 2010 | 14911 | 2010 |
| 2016 update of the EULAR recommendations for the management of early arthritis B Combe, R Landewe, CI Daien, C Hua, D Aletaha, JM Álvaro-Gracia, ... Annals of the rheumatic diseases 76 (6), 948-959, 2017 | 672 | 2017 |
| 219 Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities B Combe, A Balsa, K Winthrop, HP Tony, MC Genovese, M Harigai, ... Rheumatology 57 (suppl_3), key075. 443, 2018 | 2 | 2018 |
| 2Rheumatology Department, Pontificia Universidad Católica de Chile School of Medicine, Santiago J Durán, B Combe, J Niu, N Rincheval, C GaujouxViala, DT Felson | | |
| 320 Thursday, 04 June 2020 Scientific Abstracts B Combe, A Kivitz, Y Tanaka, D Van der Heijde, JA Simon-Campos, ... | | |
| 6 Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis Indicate a Similar Safety but a Different Drug Retention Between Abatacept, Rituximab and Tocilizumab JE Gottenberg, J Morel, A Constantin, T Bardin, AG Cantagrel, B Combe, ... ARTHRITIS & RHEUMATOLOGY 68, 2016 | 4 | 2016 |
| 772 Friday, 05 June 2020 Scientific Abstracts M Moly, C Lukas, J Morel, B Combe, G Mouterde | | |
| A 2-year double-blind comparison of etanercept (enbrel (R)) and sulfasalazine, alone and combined in patients with active rhuematoid arthritis B Combe, TK Kvien, S Fatenejad, J Wajdula Arthritis and Rheumatism 52 (9), S142-S142, 2005 | 4 | 2005 |
| A comparative controlled trial of 2 administration modalities of tiopronin in rheumatoid arthritis J Sany, B Combe, G Delecoeuillerie, S Brin, L Paolozzi Revue du Rhumatisme (Ed. Francaise: 1993) 60 (5 Pt 2), 36S-44S, 1993 | 3 | 1993 |
| A comparison of upadacitinib plus methotrexate and upadacitinib plus other csDMARDs in patients with rheumatoid arthritis: An analysis of two phase 3 studies RR Andrea, KM Joel, VB Filip, RC Sebastiao, BR Gerd, CS Heidi, ... SWISS MEDICAL WEEKLY, 8S-9S, 2019 | | 2019 |
| A comprehensive fracture prevention strategy in older adults: the European Union Geriatric Medicine Society (EUGMS) statement H Blain, T Masud, P Dargent-Molina, FC Martin, E Rosendahl, ... The journal of nutrition, health & aging 20, 647-652, 2016 | 129 | 2016 |
| A faster clinical response to Certolizumab Pegol (CZP) treatment is associated with better 52-week outcomes in patients with Rheumatoid Arthritis (RA) E Keystone, J Curtis, R Fleisehmann, P Mease, D Khanna, J Smolen, ... JOURNAL OF RHEUMATOLOGY 37 (6), 1333-1334, 2010 | 1 | 2010 |
